May. 26 at 12:56 PM
$RNAC Up to
$150 million non-dilutive credit facility from K2 HealthVentures
Initial
$50 million tranche funded, extending cash runway into 2028
Additional
$50 million and
$25 million tranches potentially available on milestones
Phase 3 AURORA MG topline data expected 1Q27 with BLA planned mid‑2027
Multiple Descartes‑08 readouts in myositis and JDM expected in 1H27
Phase 2b MG data showed average 4.8‑point MG‑ADL reduction at Month 12
$10 stock
